Neuronetics, Inc. key statistics and ratios

In fiscal 2025, Neuronetics, Inc. had return on equity of -155.7%, an operating margin of -21.1%, debt equal to 312.8% of equity and a current ratio of 2.02. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Neuronetics, Inc.: financial ratios, annual
Fiscal year	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	80.7%	76.2%	76.4%	75.4%	76.5%	78.9%	76.3%	72.5%	72.3%	48.5%	49.1%
Operating margin	−27.3%	−33.7%	−37.6%	−43.0%	−45.3%	−49.8%	−53.8%	−42.8%	−46.2%	−21.1%	−14.7%
Net margin	−32.8%	−39.7%	−45.7%	−46.4%	−55.7%	−56.4%	−57.0%	−42.3%	−58.4%	−26.1%	−19.6%
Free-cash-flow margin	−25.9%	−29.0%	−40.9%	−49.9%	−59.1%	−54.8%	−52.2%	−48.2%	−43.3%	−14.2%	−7.3%
Return on equity	—	—	—	−48.9%	−74.9%	−56.4%	−52.3%	−66.2%	−141.2%	−155.7%	−151.3%
Return on assets	—	−41.2%	−30.9%	−26.7%	−30.7%	−28.4%	−28.8%	−25.9%	−34.0%	−27.6%	−22.3%
Asset turnover	—	1.04	0.68	0.58	0.55	0.50	0.51	0.61	0.58	1.06	1.14
Current ratio	—	3.09	8.44	3.19	4.75	7.34	2.98	4.73	1.86	2.02	1.88
Debt to equity	—	—	42.8%	65.1%	137.3%	41.5%	63.0%	175.5%	216.6%	312.8%	364.1%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	24.0%	19.6%	15.6%	21.9%	18.7%	14.3%	14.3%	13.3%	17.1%	4.4%	3.8%
Capital spending as % of revenue	0.9%	1.5%	1.9%	1.3%	1.5%	4.3%	5.0%	3.3%	2.0%	0.5%	0.6%

US$ thousands unless shown otherwise. Fiscal quarters.

Neuronetics, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	75.6%	66.2%	49.2%	46.6%	45.9%	52.0%	46.9%	51.1%
Operating margin	−41.7%	−51.0%	−34.4%	−21.1%	−19.6%	−12.1%	−26.1%	−3.6%
Net margin	−72.0%	−56.3%	−39.6%	−26.6%	−24.3%	−17.1%	−31.3%	−8.3%
Free-cash-flow margin	−31.3%	−38.6%	−53.8%	−9.9%	−2.4%	1.6%	−27.9%	−3.4%
Current ratio	3.16	1.86	2.44	2.02	2.24	2.02	1.67	1.88
Debt to equity	490.4%	199.1%	156.1%	204.6%	240.1%	294.1%	462.1%	344.6%
R&D as % of revenue	13.0%	25.7%	5.1%	4.7%	4.0%	4.0%	4.0%	3.2%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 7 checks passed · June 30, 2026

What it owns · $132m

Short-term assets $53mLonger-term assets $78m

What it owes, and who funded it · $128m

Short-term liabilities $28mLonger-term liabilities $82mShareholders' equity $18m

Short-term assets cover short-term liabilities $53m of assets due within a year against $28m of liabilities due within a year.
Short-term assets cover long-term liabilities $53m short-term assets against $82m of longer-dated liabilities.
More cash than debt $19m of cash against $62m of debt.
Debt below 40% of shareholders' equity Debt is 345% of equity.
Debt burden no higher than five years ago Debt to equity moved from 41% to 345% over five years.
A year's operating cash flow covers at least 20% of debt −$10m of operating cash flow against $62m of debt.
Operating profit covers interest at least five times over Operating income of −$23m against $9m of interest.

From Neuronetics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

26 /100

Weak moat

How hard Neuronetics's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Cash operating profit has been a median -21.6% of total assets over 8 years.
Pricing power 12 / 20

Gross margin has been a median 75.2%, moving by 9.9 percentage points (standard deviation) across 9 years.
Durability 10 / 20

Operating margin has been a median -39.8%; its worst year was -57.3%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 9 years, at a median -39.5% of revenue.
Discipline 4 / 20

The diluted share count rose 213.5% over five years; stock-based pay has been a median 6.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: INFU vs STIM RXST vs STIM BBNX vs STIM LAKE vs STIM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuronetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuronetics, Inc.